Navigation Links
UAB study reveals bone coupling factor key to skeletal health
Date:7/8/2009

BIRMINGHAM, Ala. Researchers at the University of Alabama at Birmingham (UAB) have discovered a molecular coupling factor that helps bones grow and remodel themselves to stay strong, a finding that could lead to better bone-building therapies and new osteoporosis drugs, the researchers said

The coupling factor is a human protein called transforming growth factor beta-1, or TGF beta-1. Previously, scientists had searched for but missed the biological link between bone growth and bone remodeling a natural give-and-take system that is crucial to skeletal health. The discovery is reported online in the journal Nature Medicine.

"For the first time, we've identified TGF beta-1 is a coupling mechanism for bone resorption and bone formation," said Xu Cao, Ph.D., a professor in the UAB Department of Pathology and the study's senior author. "Osteoporosis, Paget's bone disease, Camurati-Engelmann disease, and many more, all involve a bone coupling disorder to some degree."

Previous research has hinted at but failed to explain the coupling role of TGF beta-1 in skeletal health. Bone remodeling occurs through resorption, the body's way of removing old and brittle bone to avoid breaks and skeletal disorders. Bone formation happens as skeletons grow and as the body works to counter bone resorption by laying down new bone.

Cao and his fellow researchers studied mice with Camurati-Engelmann disease, a genetic disorder that causes haphazard bone formation and poor skeletal health. They found the presence of TGF beta-1 in the mice could balance bone resorption and bone formation and prevent fractures and worsening bone disease.

"The current treatment for many bone diseases does two things: it stimulates osteoblasts, which help form bone, and it inhibits osteoclasts, which trigger bone resorption. That's a coupling problem, and it can lead to minimal benefit for patients," Cao said. "There is no drug designed to balance bone resorption with formation, and hopefully we can help change that."

Discovered many years ago, TGF beta-1 is one of the most abundant cytokines in bone. It has been identified in lung, liver, kidney and other organs that undergo remodeling as a natural part of the growth and aging process. Understanding the TGF beta-1 role in bone may shed light on many other diseases that have roots in biological imbalance, Cao said.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related biology news :

1. Army study improves ability to predict drinking water needs
2. Plant protein doorkeepers block invading microbes, study finds
3. Study finds role for parasites in evolution of sex
4. Canadian researchers set to study impact of nanomaterials on aquatic ecosystems
5. MS study offers theory for why repair of brains wiring fails
6. Oscar Pistorius: Previously confidential study results released on amputee sprinter
7. NSF provides $3.4 million to study climatically important Agulhas Current
8. Plant protein doorkeepers block invading microbes, study finds
9. ESHRE launches international study of polar body screening
10. Environmental cues control reproductive timing and longevity, University of Minnesota study shows
11. Study finds DNA barcoding requires caution without closer examination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... Discovery Services portfolio to include an array of biochemical analyses critical for ... data to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
Breaking Biology Technology: